SUNNYVALE, Calif., Sept. 9, 2013 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced that it's President & CEO Gerald Commissiong will make a corporate presentation at the 15 th Annual Rodman & Renshaw Global Investor Conference in New York City on September 10 th , 2013, sponsored by H.C. Wainwright & Co., LLC.
PRESENTATION INFORMATION AT A GLANCE:
| WHO: | Gerald Commissiong, President and Chief Executive Officer | |||
| WHEN: | September 10 th , 2013 at 4:55pm ET | |||
| WHERE: | Millennium Broadway Hotel in New York City, 145 West 44th Street, New York, NY | |||
| WEBCAST: | http://wsw.com/webcast/rrshq23/ambs/ ; | |||
About Amarantus
Amarantus is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Alzheimer's disease, Traumatic Brain Injury, and other human diseases. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). For further information please visit www.Amarantus.com , or connect with the Company on Facebook , LinkedIn , and Twitter .
Russell Miller, Director of Investor Relations 408.737.2734 x 109